Advertisement

Reproductive Sciences

, Volume 19, Issue 4, pp 437–448 | Cite as

Increasing Evidence for and Regulation of a Human Placental Endogenous Digitalis-Like Factor

  • Jie Ma
  • M. Sean Esplin
  • C. David Adair
  • Lorrie A. Mason
  • Steven W. GravesEmail author
Article

Abstract

Endogenous digitalis-like factors (EDLFs) appear to be hypertensiogenic and increased in the serum and placenta of women with preeclampsia (PE), a complication of pregnancy. Digibind, an anti-digoxin antibody Fab fragment, reverses in vitro effects of EDLF and in vivo features of PE. We used Digibind in a radioimmunoassay to measure EDLF and compared this to a bio-functional assay of EDLF with good agreement. These methods confirmed that human placenta was a source of EDLF, synthesizing and releasing EDLF into the media of cultured human placental tissue. Ketoconazole, a steroid synthesis inhibitor, and 17-OH progesterone, a possible substrate of steroid synthesis, were shown to inhibit or increase EDLF release respectively, suggesting overlap of synthetic pathways. Abnormalities of PE such as placental hypoxia, increased reactive oxygen species and increased proinflammatory cytokines were demonstrated to increase placental EDLF release. These findings strongly support placental production of EDLF with increased release due to features of PE.

Keywords

digitalis-like factors Digibind placenta ketoconazole 17-OH progesterone tumor necrosis factor-alpha reactive oxygen species hypoxia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Roberts JM. Preeclampsia: what we know and what we do not know. Semin Perinatal. 2000;24(1):24–28.CrossRefGoogle Scholar
  2. 2.
    Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, Mclaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989; 161(5):1200–1204.CrossRefGoogle Scholar
  3. 3.
    Zavalza-Gomez AB. Obesity and oxidative stress: a direct link to preeclampsia? Arch Gynecol Obstet. 2011;283:415–422.CrossRefGoogle Scholar
  4. 4.
    Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol. 2006;195:40–49.CrossRefGoogle Scholar
  5. 5.
    LaMarca BD, Ryan MJ, Gilbert JS, Murphy SR, Granger JP. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Current Hypertension Reports. 2007;9(6):480–485.CrossRefGoogle Scholar
  6. 6.
    Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev in Mol Med. 2006;8:1–20.CrossRefGoogle Scholar
  7. 7.
    Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation. 2002;9(3):147–160.CrossRefGoogle Scholar
  8. 8.
    Soleymanlou N, Jurisica I, Nevo O, Ietta F, Zhang X, Zamudio S. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab. 2005;90(7):4299–4308.CrossRefGoogle Scholar
  9. 9.
    Graves SW, Williams GH. An endogenous ouabain-like factor associated with hypertensive pregnancies. J Clin Endocrinol Metab. 1984;59:1070–1074.CrossRefGoogle Scholar
  10. 10.
    Valdes R Jr, Graves SW, Knight AB, Craig HR. Endogenous digoxin-immunoactivity is elevated in hypertensive pregnancy. Prog Clin Biol Res. 1985;192:229–232.PubMedGoogle Scholar
  11. 11.
    Graves SW. The possible role of digitalis-like factors in pregnancy-induced hypertension. Hypertens. 1987;10(S Pt 2):I-84-6.Google Scholar
  12. 12.
    Graves SW, Lincoln K, Cook SL, Seely EW. Digitalis-like factor and digoxin-like immunoreactive factor in diabetic women with preeclampsia, transient hypertension of pregnancy, and normotensive pregnancy. Am J Hypertens. 1995;8:5–11.CrossRefGoogle Scholar
  13. 13.
    Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, Mathews WR, Ludens JH. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA. 1991;88:6259–6263.CrossRefGoogle Scholar
  14. 14.
    Goto A, Yamada K. Purification of endogenous digitalis-like factors from normal human urine. Clin Exp Hypertens. 1998;20:551–556.CrossRefGoogle Scholar
  15. 15.
    Glatter KA, Graves SW, Hollenberg NK, Soszynski PA, Tao QF, Frem GJ, Williams GH, Lazarus JM. Sustained volume expansion and [Na, K]ATPase inhibition in chronic renal failure. Am J Hypertens, 1994;7:1016–1025.Google Scholar
  16. 16.
    Krep HH, Price DA, Soszynski P, Tao Q-F, Graves SW, Hollenberg NK. Volume sensitive hypertension and the digoxin-like factor: reversal by an Fab directed against digoxin in DOCA: salt hypertensive rats. Am J Hypertens. 1995;8:921–927.CrossRefGoogle Scholar
  17. 17.
    Krep HH, Graves SW, Price DA, Lazarus M, Ensign A, Soszynski PA, Hollenberg NK. Reversal of sodium pump inhibitor induced vascular smooth muscle contraction with Digibind: stoichiometry and its implications. Am J Hypertens. 1995;9:39–46.CrossRefGoogle Scholar
  18. 18.
    Smith TW, Butler VP Jr, Haber E, Fozzard H, Marcus FI, Bremner WF, Schulman IC, Phillips A. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: experience in 26 cases. N Engl J Med. 1982;307:1357–1362.CrossRefGoogle Scholar
  19. 19.
    Adair CD, Buckalew VM, Graves SW, Lam GK, Johnson DD, Saade G, Lewis DF, Robinson C, Danoff TM, Chauhan N, Hopoate-Sitake M, Porter KB, Humphrey RG, Trofatter KF, Amon E, Ward S, Kennedy L, Mason L, Johnston JA. Digoxin immune Fab treatment for severe preeclampsia. Amer J Perinatol. 2010;27:655–662.CrossRefGoogle Scholar
  20. 20.
    Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P-450 dependent enzymes. J. Clin. Invest. 1983;71:1495–1499.CrossRefGoogle Scholar
  21. 21.
    Miossec P, Archambeaud-Mouveroux F, Teissier MP. Inhibition of steroidogenesis by ketoconazole. Therapeutic uses. Ann Endocrinol (Paris). 1997:58:494–502.Google Scholar
  22. 22.
    Kraemer FB, Spilman SD. Effect of ketoconazole on cholesterol synthesis. J Pharmacol Exp Ther. 1986;238:905–911.PubMedGoogle Scholar
  23. 23.
    Kempen HJ, Van son K, Cohen LH, Griffioen M. Effect of ketoconazole on cholesterol synthesis and on HMG-CoA reductase and LDL-receptor activities in Hep G2 cells. Biochem Pharmacol. 1987;36:1245–1249.CrossRefGoogle Scholar
  24. 24.
    Shibata Y, Takahashi H, Chiba M, Ishii Y. A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method. Drug Metab Pharmacokinet. 2008;23:328–339.CrossRefGoogle Scholar
  25. 25.
    Levy MJ, Smotrich DB, Widra EA, Sagoskin AW, Murray DL, Hall JL. The predictive value of serum progesterone and 17-OH progesterone levels on in vitro fertilization outcome. Amer Fertility Soc. 1995;12:161–166.Google Scholar
  26. 26.
    Li H, Gu B, Zhang Y, Lewis DF, Wang Y. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta. 2005;26:210–217.CrossRefGoogle Scholar
  27. 27.
    Hopoate-Sitake ML, Adair CD, Mason LA, Torres C, Kipikasa J, Graves SW. Digibind reverses inhibition of cellular Rb+ uptake caused by endogenous sodium pump inhibitors present in serum and placenta of women with preeclampsia. Reproductive Sci. 2011;18:190–199.CrossRefGoogle Scholar
  28. 28.
    Diamandis EP, Papanastaslou-Diamandi A, Soldin SJ. Digoxin immunoreactivity in cord and maternal serum and placental extracts. Partial characterization of immunoreactive substances by high-performance liquid chromatography and inhibition of Na+, K+-ATPase. Clin Biochem. 1985;18:48–55.CrossRefGoogle Scholar
  29. 29.
    Morris JF, Poston L, Wolfe CD, Hilton PJ. A comparison of endogenous digoxin-like immunoactivity and sodium transport inhibitory activity in umbilical arterial and venous serum. Clin Sci (Lond). 1988;75:577–579.CrossRefGoogle Scholar
  30. 30.
    Hilton PJ, White RW, Lord GA, Garner GV, Gordon DB, Hilton MJ, Forni LG, McKinnon W, Ismail RMD, Keenan M, Jones K, Morden WE. An inhibitor of the sodium pump obtained from human placenta. Lancet. 1996;348:303–305.CrossRefGoogle Scholar
  31. 31.
    Gao S, Chen Z, Xu Y. The source of endogenous digitalis-like substance in normal pregnancy. Zhonghua Fu Chan Ke Za Zhi. 1998;33:539–541.PubMedGoogle Scholar
  32. 32.
    Fedorova OV, Tapilskaya NI, Bzhelyansky AM, Frolova EV, Nikitina ER, Reznik VA, Kashkin VA, Bagrov AY. Interaction of Digibind with endogenous cardiotonic steroids from preeclamptic placentae. J Hypertens. 2010;28:361–366.CrossRefGoogle Scholar
  33. 33.
    Ugele B, Simon S. Uptake of dehydroepiandrosterone-3sulfate by isolated trophoblasts from human term placenta, JEG-3, BeWo, Jar, BHK cells and BHK cells transfected with human sterylsulfatase-cDNA. J Steroid Biochem Mol Biol. 1999;71:203–211.CrossRefGoogle Scholar
  34. 34.
    Fang S, Shoko H, Yukako O, Sakiko H, Kyoko T, Yasuko Y, Sadako T, Shosuke K. Evaluation of oxidative stress based on lipid hydroperoxide, vitamin C and vitamin E during apoptosis and necrosis caused by thioacetamide in rat liver. BBA-Molec Basis Disease. 2000;1500:181–185.CrossRefGoogle Scholar
  35. 35.
    Rabe T, Brandstetter K, Kellermann J, Runnebaum B. Partial characterization of placental 3 beta-hydroxysteroid dehydrogenase (EC1.1.1.145), delta 4–5 isomerase (EC 5.3.3.1)in human term placenta. J Steroid Biochem. 1982;17:427–433.CrossRefGoogle Scholar
  36. 36.
    Powell WA, Challis JR, Influence of 20 alpha-dihydropro-gesterone on progesterone output by human chorion explants. Gynecol Obstet Invest. 1986;22:73–78.CrossRefGoogle Scholar

Copyright information

© Society for Reproductive Investigation 2012

Authors and Affiliations

  • Jie Ma
    • 1
  • M. Sean Esplin
    • 2
  • C. David Adair
    • 3
  • Lorrie A. Mason
    • 3
  • Steven W. Graves
    • 1
    • 4
    Email author
  1. 1.Department of Chemistry and BiochemistryBrigham Young UniversityProvoUSA
  2. 2.Department of Obstetrics and GynecologyUniversity of Utah School of MedicineSalt Lake CityUSA
  3. 3.Department Obstetrics and GynecologyUniversity of Tennessee College of Medicine, Baroness Erlanger HospitalChattanoogaUSA
  4. 4.ProvoUSA

Personalised recommendations